Head-To-Head Contrast: Statera Biopharma (STAB) versus The Competition

Institutional & Insider Ownership

39.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Statera Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Statera Biopharma Competitors	-2,625.49%	-359.57%	-43.35%

Risk and Volatility

Statera Biopharma has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Statera Biopharma’s peers have a beta of 10.24, suggesting that their average stock price is 924% more volatile than the S&P 500.

Valuation & Earnings

This table compares Statera Biopharma and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Statera Biopharma	N/A	N/A	0.00
Statera Biopharma Competitors	$440.84 million	-$69.10 million	-9.37

Statera Biopharma’s peers have higher revenue, but lower earnings than Statera Biopharma. Statera Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

About Statera Biopharma

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.